StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Candesartan Cilexetil

HCID 2540
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
145040-37-5
Standard-SMILES
CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
InChIKey
GHOSNRCGJFBJIB-UHFFFAOYSA-N
Summenformel
C33H34N6O6
Durchschnittliche Molmasse
610,7 g/mol
Monoisotopische Masse
610,25398283

Überblick

Candesartan cilexetil is a member of biphenyls.

Namen und Bezeichner

Bevorzugter Name
Candesartan Cilexetil
IUPAC
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
Englischer Name
Candesartan cilexetil
Summenformel
C33H34N6O6
Molmasse
610.66

Namen und Synonyme

Candesartan cilexetil145040-37-5AtacandTCV-116AmiasDTXSID5020239NSC-758697R85M2X0D68DTXCID50239Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester1H-Benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)-Candesartan 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
Weitere Namen anzeigen
Candesartan cilexetiBlopressCandesartan cilexetil for peak identificationtcv116exetiLTCY 116CandestartanCandesartan CiLCadesartan cilexetil
RefChem:566661-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate(1RS)-1-(Cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylateRatacandParapresKenzencandesartancilexetilCANDESARTAN CILEXTIL

Eigenschaften

Berechnete Struktureigenschaften

XLogP
7
Polarare Oberfläche (TPSA)
143 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
10
Frei drehbare Bindungen
13
Schwere Atome
45
Formalladung
0
Komplexität
962

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals

Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section · 2 Einträge

242.2 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID5020239]

241.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
168 · 168-170C
Siedepunkt
843.3 · 843.3±75.0 °C(Predicted)
Dichte
1.37 · 1.37±0.1 g/cm3(Predicted)
storage temp.
2 · 2-8°C
Löslichkeit
15 mg/mL · DMSO: ≥15mg/mL
pka
3.55 · pKa 3.55 (H2O t=25.0 I=0.025) (Uncertain);5.91(H2O t=25.0 I=0.025) (Uncertain)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 0.5% (1 of 197) of reports.

Danger

H302 (26.9%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P263, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 197 reports by companies from 20 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (26.9%)

Toxikologische Informationen

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Candesartan cilexetil

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

EPA Human Health Benchmarks for Pharmaceuticals · 6 Einträge

Candesartan cilexetil

0.2

0.8

Blood pressure response is dose related over the range of 2 to 32 mg. Candesartan cilexetil tablets can be administered once or twice daily with total daily doses ranging from 8 mg to 32 mg.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 8 mg/day, Lowest Therapeutic Dose (LTD): 0.1 mg/kg-day, and Screening Dose: 0.00003 mg/kg-day.

27-Jun-17

Sicherheitsdaten

Chemie und Industrie

Pharmakologische Informationen

Protein BindingCandesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.
Pharmacodynamics · 1 Eintrag

Candesartan cilexetil is an ARB prodrug that is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS. RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.

Mechanism of Action · 1 Eintrag

Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion.

Zugehörige Reaktionen

11
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 11804
HRID 11804als Produkt
Reaktionsgleichung von HRID 11805
HRID 11805als Produkt
Reaktionsgleichung von HRID 11806
HRID 11806als Produkt
Reaktionsgleichung von HRID 11807
HRID 11807als Produkt
Reaktionsgleichung von HRID 324526
HRID 324526als Edukt
Reaktionsgleichung von HRID 549973
HRID 549973als Edukt
Reaktionsgleichung von HRID 640734
HRID 640734als Edukt
Reaktionsgleichung von HRID 640735
HRID 640735als Produkt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
145040-37-5
PubChem CID
2540
DTXSID
DTXSID5020239
ChEMBL
CHEMBL1014
ChEBI
CHEBI:3348
UNII
R85M2X0D68
EC Number
627-030-2
Nikkaji
J1.640.921I
Aggregatzustand
powder
Farbe
white to beige
Merck
14 · 14,1739
BCS Class
2 · 2
Major Application
pharmaceutical (small molecule)
InChIKey
GHOSNRCGJFBJIB-UHFFFAOYSA-N
SMILES
C1(OCC)N(CC2=CC=C(C3=CC=CC=C3C3=NNN=N3)C=C2)C2=C(C(OC(OC(OC3CCCCC3)=O)C)=O)C=CC=C2N=1
CAS Datenbank
145040 · 145040-37-5(CAS DataBase Reference)
wgk
3
hs_code
2933990099
RTECS-Nr.
DD6672500
risk_code
20/21/22-36/37/38-50-48/20-61
Toxizität
dog,LD50,oral,> 2gm/kg (2000mg/kg),Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 42, Pg. 406, 2000.
hazard_code
Xn,N,T
safety_code
26-36-61-45-53
Speicherklasse
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
Repr. 1BSTOT RE 2 Oral
Biological Half-Life
Approximately 9 hours.
Metabolism/Metabolites · 1 Eintrag

The prodrug candesartan cilexetil undergoes rapid and complete ester hydrolysis in the intestinal wall to form the active drug, candesartan. Elimination of candesartan is primarily as unchanged drug in the urine and, by the biliary route, in the feces. Minor hepatic metabolism of candesartan (<20%) occurs by O-deethylation via cytochrome P450 2C9 to form an inactive metabolite. Candesartan undergoes N-glucuronidation in the tetrazole ring by uridine diphosphate glucuronosyltransferase 1A3 (UGT1A3). O-glucuronidation may also occur. 75% of candesartan is excreted as unchanged drug in urine and feces.

FDA Pharmacological Classification · 2 Einträge

CANDESARTAN CILEXETIL

Angiotensin 2 Receptor Blocker [EPC]; Angiotensin 2 Receptor Antagonists [MoA]

MeSH Pharmacological Classification · 2 Einträge

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.

Absorption, Distribution and Excretion · 4 Einträge

Following administration of the candesartan cilexetil prodrug, the absolute bioavailability of candesartan was estimated to be 15%. Food with a high fat content has no effect on the bioavailability of candesartan from candesartan cilexetil.

When candesartan is administered orally, about 26% of the dose is excreted unchanged in urine. Candesartan is mainly excreted unchanged in urine and feces (via bile).

0.13 L/kg

0.37 mL/min/kg

Verwendung und Herstellung

UsesUse (kg) in Switzerland (2009): >500

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

1-Iodoethyl cyclohexyl carbonateSchwefelsureAzidotrimethyltinChlortriphenylmethanNatriumhydroxid3-NitrophthalsureKaliumcarbonat4-Bromomethyl-2-cyanobiphenylNatriumazidStannous chloride dihydrate